The suit alleges that the drug-makers had illegal conspiracies in place to unreasonably restrain trade, inflate and manipulate prices, and reduce competition for two drugs: doxycycline hyclate delayed release and glyburide. The two drugs are used to treat a respiratory tract infections and diabetes.

New York Attorney General Eric Schneiderman announced today that he is joining 19 other state attorney generals in filing a federal antitrust lawsuit against a group of generic drug companies.

The suit alleges that the drug-makers had illegal conspiracies in place to unreasonably restrain trade, inflate and manipulate prices, and reduce competition for two drugs: doxycycline hyclate delayed release and glyburide. The two drugs are a antibiotic for respiratory tract infections and an oral diabetes medication, respectively.

The companies are Heritage Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., Citron Pharma, LLC, Mayne Pharma (USA), Inc., Mylan Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.

The suit is the result of an investigation originally begun by the state of Connecticut, and the complaint alleges that the drug companies coordinated their actions through various means.